Veracyte Inc (VCYT)
19.90
+0.07
(+0.35%)
USD |
NASDAQ |
Apr 24, 16:00
19.90
0.00 (0.00%)
Pre-Market: 08:50
Veracyte Enterprise Value: 1.277B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 24, 2024 | 1.277B |
April 23, 2024 | 1.272B |
April 22, 2024 | 1.274B |
April 19, 2024 | 1.244B |
April 18, 2024 | 1.225B |
April 17, 2024 | 1.199B |
April 16, 2024 | 1.204B |
April 15, 2024 | 1.238B |
April 12, 2024 | 1.302B |
April 11, 2024 | 1.340B |
April 10, 2024 | 1.338B |
April 09, 2024 | 1.392B |
April 08, 2024 | 1.337B |
April 05, 2024 | 1.294B |
April 04, 2024 | 1.298B |
April 03, 2024 | 1.332B |
April 02, 2024 | 1.323B |
April 01, 2024 | 1.408B |
March 28, 2024 | 1.447B |
March 27, 2024 | 1.414B |
March 26, 2024 | 1.372B |
March 25, 2024 | 1.360B |
March 22, 2024 | 1.367B |
March 21, 2024 | 1.403B |
March 20, 2024 | 1.406B |
Date | Value |
---|---|
March 19, 2024 | 1.410B |
March 18, 2024 | 1.404B |
March 15, 2024 | 1.367B |
March 14, 2024 | 1.379B |
March 13, 2024 | 1.440B |
March 12, 2024 | 1.459B |
March 11, 2024 | 1.485B |
March 08, 2024 | 1.489B |
March 07, 2024 | 1.491B |
March 06, 2024 | 1.461B |
March 05, 2024 | 1.506B |
March 04, 2024 | 1.550B |
March 01, 2024 | 1.585B |
February 29, 2024 | 1.551B |
February 28, 2024 | 1.568B |
February 27, 2024 | 1.557B |
February 26, 2024 | 1.552B |
February 23, 2024 | 1.449B |
February 22, 2024 | 1.567B |
February 21, 2024 | 1.581B |
February 20, 2024 | 1.617B |
February 16, 2024 | 1.596B |
February 15, 2024 | 1.637B |
February 14, 2024 | 1.654B |
February 13, 2024 | 1.545B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
643.66M
Minimum
Mar 18 2020
5.083B
Maximum
Feb 09 2021
1.752B
Average
1.606B
Median
Jul 11 2022
Enterprise Value Benchmarks
Fonar Corp | 43.81M |
XWELL Inc | -7.551M |
ProPhase Labs Inc | 96.83M |
Applied DNA Sciences Inc | 0.5914M |
OncoCyte Corp | 23.38M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -28.29M |
Revenue (Quarterly) | 98.20M |
Total Expenses (Quarterly) | 101.17M |
EPS Diluted (Quarterly) | -0.39 |
Gross Profit Margin (Quarterly) | 70.09% |
Profit Margin (Quarterly) | -28.81% |
Earnings Yield | -5.18% |
Normalized Earnings Yield | -0.7793 |